loading
Precedente Chiudi:
$0.9119
Aprire:
$0.9402
Volume 24 ore:
1.98M
Relative Volume:
0.52
Capitalizzazione di mercato:
$143.78M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
23.31
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
+4.93%
1M Prestazione:
-35.26%
6M Prestazione:
-77.75%
1 anno Prestazione:
-88.77%
Intervallo 1D:
Value
$0.90
$0.9785
Intervallo di 1 settimana:
Value
$0.8842
$0.9967
Portata 52W:
Value
$0.591
$8.45

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name
Nome
Ironwood Pharmaceuticals Inc
Name
Telefono
617-621-7722
Name
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Name
Dipendente
253
Name
Cinguettio
@ironwoodpharma
Name
Prossima data di guadagno
2025-02-21
Name
Ultimi documenti SEC
Name
IRWD's Discussions on Twitter

Confronta IRWD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
IRWD
Ironwood Pharmaceuticals Inc
0.9323 143.78M 400.57M 9.21M 146.36M 0.04
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.44 68.46B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.32 47.30B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.70 45.89B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.19 17.90B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
294.60 13.14B 2.76B 1.11B 898.10M 22.77

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-15 Downgrade Jefferies Buy → Hold
2025-04-15 Downgrade Wells Fargo Overweight → Equal Weight
2025-04-14 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
2024-09-09 Iniziato Leerink Partners Market Perform
2024-08-08 Downgrade CapitalOne Overweight → Equal Weight
2024-01-17 Iniziato Craig Hallum Buy
2023-12-14 Iniziato Wells Fargo Overweight
2023-11-09 Iniziato Jefferies Buy
2023-09-28 Iniziato JMP Securities Mkt Outperform
2022-09-02 Iniziato CapitalOne Overweight
2022-04-22 Iniziato Piper Sandler Overweight
2020-09-30 Downgrade Wells Fargo Overweight → Equal Weight
2020-06-17 Iniziato Northland Capital Outperform
2019-07-10 Ripresa Credit Suisse Neutral
2019-03-27 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2019-02-25 Aggiornamento H.C. Wainwright Sell → Neutral
2019-01-24 Aggiornamento JP Morgan Underweight → Neutral
2018-11-07 Downgrade Credit Suisse Outperform → Neutral
2018-11-07 Downgrade JP Morgan Neutral → Underweight
2018-07-23 Iniziato H.C. Wainwright Sell
2018-05-09 Downgrade Morgan Stanley Equal-Weight → Underweight
2018-01-05 Downgrade BofA/Merrill Buy → Underperform
2017-12-06 Downgrade Mizuho Buy → Neutral
2017-07-21 Downgrade JP Morgan Overweight → Neutral
2017-05-03 Iniziato Wells Fargo Outperform
2017-04-07 Reiterato Mizuho Buy
2017-02-22 Reiterato Barclays Equal Weight
2016-11-04 Reiterato Mizuho Buy
2016-10-24 Reiterato Wedbush Neutral
2016-10-10 Reiterato Mizuho Buy
2016-09-27 Reiterato WallachBeth Hold
Mostra tutto

Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie

pulisher
May 01, 2025

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView

Apr 25, 2025
pulisher
Apr 23, 2025

Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus

Apr 23, 2025
pulisher
Apr 22, 2025

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com

Apr 22, 2025
pulisher
Apr 18, 2025

Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com

Apr 18, 2025
pulisher
Apr 17, 2025

Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Top Midday Decliners - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood to considers merger opportunities after FDA setback - The Business Journals

Apr 14, 2025
pulisher
Apr 14, 2025

Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial - MarketWatch

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood requires new trial for SBS drug approval - Investing.com

Apr 14, 2025

Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Silver Ronald
Principal Accounting Officer
Feb 10 '25
Sale
1.76
12,048
21,204
279,655
Shetzline Michael
SVP, CMO, Head-Res&Drug
Feb 10 '25
Sale
1.76
41,269
72,633
554,007
John Minardo
Chief Legal Officer
Feb 10 '25
Sale
1.76
38,938
68,531
408,132
Martini Gregory S.
Chief Financial Officer
Feb 10 '25
Sale
1.76
12,052
21,212
183,810
$31.78
price up icon 3.92%
$9.75
price up icon 2.96%
$108.74
price up icon 2.66%
$8.65
price up icon 2.13%
$109.68
price up icon 2.90%
$294.60
price up icon 0.26%
Capitalizzazione:     |  Volume (24 ore):